Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE Combined With Bevacizumab in BCLC-B HCC
NCT05883176Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2023
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05883176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05883176.